OVERVIEW OF ACTIVITY
Nearly one million men each year are newly diagnosed with prostate cancer (PCa), making it the fifth most common cancer in both sexes combined and the second most common among men worldwide. In 2014 in the United States alone it is estimated that the disease will culminate in 233,000 new cases and 29,480 deaths. As such, PCa has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in the treatment of PCa to assist medical oncologists, hematologists and hematology-oncology fellows, radiation oncologists, urologists, oncology nurses and other select healthcare practitioners in the formulation of up-to-date and appropriate treatment strategies.

LEARNING OBJECTIVES

• Consider the decision-making of clinical investigators with expertise in the management of hormone-sensitive PCa, and use this information in the future selection of chemotherapy regimens — with or without androgen deprivation therapy — for patients with this disease.
• Assess the optimal dose, duration and timing of docetaxel administration for patients with hormone-sensitive PCa.
• Evaluate the effects of patient age, performance status and level of disease burden on faculty treatment preferences for patients with hormone-sensitive PCa.

ACCREDITATION STATEMENT

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a text component. The participant should review the treatment preference matrices.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Andrew J Armstrong, MD, ScM
Associate Professor of Medicine and Surgery
Duke Cancer Institute
Duke University
Durham, North Carolina

Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Consulting Agreements: Active Biotech AB, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Ipsen, Sanofi; Contracted Research: Active Biotech AB, Astellas, Bristol-Myers Squibb Company, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Ipsen, Janssen Pharmaceuticals Inc, KangLaiTe USA, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Speakers Bureau: Amgen Inc, Dendreon Corporation, Pfizer Inc, Sanofi.

Johann S de Bono, MBChB, MSc, PhD
Professor of Experimental Cancer Medicine
and Honorary Consultant in Medical Oncology
Head of Clinical Studies Division,
of Drug Development Unit and of the Prostate Cancer Targeted Therapy Group
The Institute of Cancer Research and
Royal Marsden NHS Foundation Trust
Sycamore House
Sutton, Surrey, United Kingdom

Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Sanofi; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Sanofi.

Prof Ronald de Wit, MD, PhD
Medical Oncologist
Erasmus MC Cancer Institute
Rotterdam, the Netherlands

Advisory Committee: Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Astellas, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Roche Laboratories Inc, Sanofi; Contracted Research: Sanofi.

Leonard G Gomella, MD
The Bernard W Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Sidney Kimmel Cancer Center
Clinical Director, Jefferson Sidney Kimmel Cancer Center Network
Editor-in-Chief, Canadian Journal of Urology
Philadelphia, Pennsylvania

Advisory Committee: Dendreon Corporation, GlaxoSmithKline; Consulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Janssen Pharmaceuticals Inc; Contracted Research: Astellas, Dendreon Corporation, Janssen Pharmaceuticals Inc.

Celestia S Higano, MD
Professor of Medicine and Urology
University of Washington School of Medicine
Member, Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Advisory Committee: Abbott Laboratories, Astellas, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Millennium: The Takeda Oncology Company; Consulting Agreements: Abbott Laboratories, Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Genentech BioOncology, Medivation Inc, Millennium: The Takeda Oncology Company, Pfizer Inc; Contracted Research: Aragon Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Genentech BioOncology, Medivation Inc, Millennium: The Takeda Oncology Company, Sanofi, Teva Pharmaceutical Industries Ltd; Co-ownership: CTI BioPharma. None of the products currently approved or in development at CTI BioPharma pertain to any form of treatment for prostate cancer. As such, Dr Higano’s involvement with CTI BioPharma does not pose any conflict of interest in her participation in this CME activity.

Philip Kantoff, MD
Chair, Executive Committee for Clinical Research
Chief Clinical Research Officer
Chief, Division of Solid Tumor Oncology
Vice Chair, Department of Medical Oncology
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Astellas, Auven Therapeutics, Bellicum Pharmaceuticals Inc, BIND Therapeutics Inc, Blend Therapeutics, Endocyte/TRM Oncology, Medivation Inc, Metamark Genetics Inc, OncoCellMDx Inc, Progenics Pharmaceuticals Inc, Sanofi, SOTIO LLC, Tokai Pharmaceuticals; Consulting Agreements: Amgen Inc, Aragon Pharmaceuticals Inc, Archimedes Pharma US Inc, Bayer HealthCare Pharmaceuticals, BN ImmunoTherapeutics Inc, Celgene Corporation, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, GTx Inc, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, MorphoSys, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd/OncoGenex Pharmaceuticals Inc.

Eric A Klein, MD
Chairman, Glickman Urological and Kidney Institute
Cleveland Clinic
Cleveland, Ohio

Clinical Trial Support: Medivation Inc; Consulting Agreements: Genomic Health Inc, Medivation Inc; Contracted Research: Genomic Health Inc.

Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Millennium: The Takeda Oncology Company, Pfizer Inc, Sanofi; Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Sanofi; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc.

A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Progenics Pharmaceuticals Inc, Sanofi.

Neal D Shore, MD
Medical Director, Carolina Urology Research Center
Myrtle Beach, South Carolina

Consulting Agreements: Abbott Laboratories, Astellas, Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Millennium: The Takeda Oncology Company, Pfizer Inc, Sanofi.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Millennium: The Takeda Oncology Company and Sanofi.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: January 2015
Expiration date: January 2016